CanSino Biologics Launches Phase I Trial for Inhaled TB Booster in Indonesia
CanSino Biologics Inc. has launched a Phase I clinical trial for its inhaled tuberculosis vaccine in Indonesia, enrolling the first patient. The trial will assess the safety and immunogenicity of a single dose of the inhaled TB Booster in adults aged 18 to 49. The vaccine aims to stimulate an immune response in the lungs to combat tuberculosis. Results are pending.
CanSino Biologics Inc. has announced the initiation of a Phase I clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), referred to as the inhaled TB Booster, in Indonesia. The first patient has been formally enrolled in the study. The trial is designed to evaluate the safety and immunogenicity of a single dose of the inhaled TB Booster in adults aged 18 to 49 years. The vaccine, delivered via aerosol inhalation, aims to stimulate an immune response in the lungs to help clear tuberculosis bacilli and control latent infection. Results from this clinical trial have not yet been presented and will be available in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
